ClinicalTrials.gg
CompletedNCT05064371Updated Jan 14, 2026

Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

A Phase 3 interventional study of Eptinezumab in Migraine, sponsored by H. Lundbeck A/S. Completed at 17 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
14th of 21
160 · median 193
Started
2021
with 4 others
Phase 3
13 of 21
5 open now
Registered
13th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 14th largest by enrollment, is one of 5 that started in 2021, is one of 13 in phase 3, and was the 13th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

This study is an open label extension study, which means that the participants from the Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility Criteria, and continue to receive the study drug eptinezumab. The main goal of this study is to investigate long-term safety and tolerability of eptinezumab in Japanese migraine participants.

Read the detailed description

The total study duration from the Baseline Visit to the Safety Follow-up Visit is approximately 68 weeks and includes an Open-Label Treatment Period (60 weeks) and a Safety Follow-up Period (8 weeks).

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The participant has completed the Primary Outcome Visit (Visit 5) of the lead-in Study 19140A immediately prior to enrolment into this study.
  • The participant is indicated for 60-week preventive treatment of chronic migraine with eptinezumab according to the clinical opinion of the investigator.

Key Exclusion Criteria:

  • The participant has a serious adverse event (SAE) or a moderate or severe ongoing AE from the Lead-In study considered a potential safety risk by the investigator.
  • The participant has a change in vital signs or (ECG) from the Lead-In study considered a potential safety risk by the investigator.
  • The participant has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Eptinezumab

    Participants will receive eptinezumab 100 milligrams (mg) at the Baseline visit (Week 0) and eptinezumab 100 mg or 300 mg (depending upon the treatment response) at Weeks 12, 24, 36, and 48 by intravenous (IV) infusions.

    Drug: Eptinezumab

Interventions

  • Concentrate for solution for IV infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: From Baseline to Week 68

Secondary outcomes

  1. Change From Baseline in the Number of Monthly Migraine Days

    Time frame: Baseline, Week 60

  2. Response: Number of Participants With ≥50% Reduction From Baseline in Monthly Migraine Days (MMDs)

    Time frame: Baseline to Week 60

  3. Change From Baseline in the Headache Impact Test (HIT-6) Score

    Time frame: Baseline, Week 60

  4. Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) Score

    Time frame: Baseline, Week 60

  5. Patient Global Impression of Change (PGIC) Score

    Time frame: Baseline to Week 60

  6. Change From Baseline in the Most Bothersome Symptom (MBS) Score

    Time frame: Baseline, Week 60

07

Study locations

17 sites
  • DOI Clinic Internal Medicine
    Hiroshima-Shi Naka-Ku, Hiroshima 730-0031, Japan
  • Jinnouchi Neurosurgery Clinic
    Kasuga-Shi, Hukuoka 816-0802, Japan
  • Ikeda Neurosurgical Clinic
    Kasuga-Shi, Hukuoka 816-0824, Japan
  • Mito Kyodo General Hospital
    Mito, Ibaraki 310-0015, Japan
  • Iwate Medical University Uchimaru Medical Center
    Morioka, Iwate 020-0023, Japan
  • Atsuchi Neurosurgery Hospital
    Kagoshima, Kagoshima-ken 892-0842, Japan
  • Shin Matsudakai Atago Hospital
    Kochi, Kôti 780-0051, Japan
  • Sendai Headache and Cranial Nerves Clinic
    Sendai-Shi Taihaku-Ku, Miyagi 982-0014, Japan
  • Saitama Neuropsychiatric Institute
    Saitama-Shi, Saitama 338-8577, Japan
  • Moriyama Neurological Center Hospital
    Edogawa-Ku, Tokyo 134-0085, Japan
  • Tokyo headache clinic
    Shibuya-Ku, Tokyo 151-0051, Japan
  • Nagamitsu Clinic
    Hofu-Shi, Yamaguchi 747-0802, Japan
  • Tatsuoka Neurology Clinic
    Kyoto Shimojo-ku, 680-8811, Japan
  • Dokkyo Medical University Hospital
    Mibu-machi, 321-0293, Japan
  • Japanese Red Cross Shizuoka Hospital
    Shizuoka, 420-0853, Japan
  • Toyota Memorial Hospital
    Toyota-shi, 471-8513, Japan
  • Tominaga Hospital
    Osaka, Ã"saka 556-0017, Japan
08

References and documents

Publications

  • Takeshima T, Danno D, Imai N, Suzuki K, Ettrup A, Jensen S, Josiassen MK, Mittoux A, Matsumori Y. Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial. J Headache Pain. 2025 Nov 22;26(1):275. doi: 10.1186/s10194-025-02214-w. PubMed 41275111 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2024, 32 months.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 32 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 1, 2021
StartActual
Sep 21, 2021
Primary completionActual
Jun 8, 2024
CompletionActual
Jun 8, 2024
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05064371
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Sep 21, 2021
Primary completion
Jun 8, 2024
Completion
Jun 8, 2024
Last update
Jan 14, 2026

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion